Miller K, Wang M, Gralow J, et al

Miller K, Wang M, Gralow J, et al. same time, it would make little sense to have an agent that reduces chances of dying of malignancy but increases off-target deaths; hence, the need for verification of OS. Phase III trials that statement on significant PFS benefits without OS prolongation become the apples of discord in […]